Morning Overview on MSN
A targeted pill and a custom mRNA vaccine are both beating back pancreatic cancer in early trials — cracking open one of medicine’s hardest tumors
Pancreatic ductal adenocarcinoma has a five-year survival rate of roughly 13 percent, according to the American Cancer ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy ...
Morning Overview on MSN
Two new pancreatic cancer treatments — a targeted pill and a personalized mRNA vaccine — are beating back one of medicine’s deadliest tumors in early trials
Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after ...
Overall, treatment of metastatic triple-positive breast cancer is shifting toward precision-driven regimens that combine HER2 blockade with endocrine and targeted agents tailored to disease burden, ...
Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors. Under current NCCN guidelines as of mid-December 2025, ...
A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical ...
Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...
The metastatic breast cancer (mBC) landscape is evolving rapidly due to the increasing prevalence of ESR1 mutations, a key driver for hormone receptor-positive (HR+) patients. ESR1 mutations, ...
NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth ...
Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results